Member Info for Doc.Daneeka

Gunther Bayerlot also a prime candidate

Dr Mark ... first letter of surname also looks like an M Or N) then maybe an I - but seems to only be 3 letters long. V odd as it's all CAPS and the angle is not too steep so we should see 4th and 5th letters if there are any.

That's all I have without Rick Deckard's photo enhancer. "Enhance 57 to 19. Track 45 left. Stop. Enhance 15 to 23. "

https://www.youtube.com/watch?v=hHwjceFcF2Q

I knew you would Mani - and equally sure she will reply :)

Well done Paladin !

If anyone can ask on twitter that would probably be the fastest way to finding out. He's not dressed as the others which suggests he's not a SyN employee - but then if he was an important stranger - or even an unimportant stranger it would usually be a courtesy to name check him. If he was someone big from FDA or a pharma and it meant something they'd have either not put it out at all or put it out seperately with his permission.
So my conclusion is he either IS a synner - if we have a Dr Mark - or he's from a US partner or the one of the conf organisers.

Ok Mani if you think that's a worthy addition to the pool of knowledge.
I'd say we knew who he was and what he does.

Ask Brooke who the fella in the middle is - that really would be useful.

Plus he's our Chief Commercial Officer

I'm hypothesising that NIH has a choice to make. Of course we don't have a choice - we'll take whatever we're given.

STRIVE will be by far the fastest route to EUA and commercialisation. Even after the winter surge there will still be plenty of sick patients in the Strive network's hospitals. Plenty for 1000 patient trial anyway. As long as the delays with starting are not evidence that the funding is in jeopardy. Flu trials 10s of thousands of patients. Recover - up to 4 year long studies.

If there's a JV it should still be with a partner who wants to help us turn the Sprinter promise into an EUA for Covid.

you're mad mani - how was that response not calm. ? I wasn't calling you stupid - but it would be seriously mad to put us on Recover and not STRIVE - because if we get onto STRIVE we'll be generating the LC data anyway.

Well we could all agree that we have a good case for both, but in terms of resources it would be really stupid to just test SNG for LC - when the case would be proven or unproven by STRIVE anyway as well as potentially adding a new drug for the most vulnerable when they arrive in hospitals.

Algy of course that's logical and correct and it's the reason why all successful vaccines and therapeutics should reduce Long Covid to a greater or lesser extent. Omicron is not producing the same LC effects that Delta did - so it's reasonable to suppose that most of the Recover trail will be looking at the long term existing effects - the ME end of the LC spectrum, rather than viral clearance. But the significance is that Paxlovid is the first selected trialist and its been chosen for viral clearance so NIH has shown where it sees the priorities. It's inclusion is entirely due to the accident of not working properly with the first 5 day dose but then patients recovering well when given a second dose. (which they might well have done anyone 10 or 15 days after first inffection. Fauci was much sicker when he had the rebound infection )

It's significant that the NIH realises there will be no single "cure" as such for the long term effects, and those poor Delta long haulers will be treated with the drugs that come closest to treating the symptoms they present with, and with whatever extrsa help can be unearthed in trials - but the NIH is rightly saying - ok bad luck to all that - but we're starting with a therapeutic that clears out any residual virus first, so that we at least know it's not continuing to do damage.

Maybe you might use the analogy that's been used many times in relation to Covid - and in relation to SNG. The idea of a fire raging. RM was talking abourt the cytokine storm when he talked about the drug loving a fire to put out - and if you consider viral clearance you'd maybe think of it as a fire department continuing "damping down" long after a fire appears to be out. Dexa was authorised for this purpose but it has no impact whatsoever on viral clearance and can of course be daming to the immune system at the same time as calming down the storm.
Damping down gets down into the hot heart of the embers and makes sure they can't reignite. That's what this is about - and there's plenty of reason - as I posted before, to believe that SNG would do a better job than Paxlovid.

Reposting this. Paxlovid has made it onto the study on very limited LC data, and I suspect the usual big pharma push ( I found one pre-print paper from May with just 3 patients - 2 of whom did well and the third who had a rebound infection and did badly) There must be other work out there but i couldn't see it. We know Pax and Mol have been collecting LC data just as Synairgen did and perhaps this has been fed into the equation without being published.
The justification for Paxlo being included is it's potential for the viral clearance ...
"The trial will investigate a leading theory of the cause of long COVID, which holds that fragments of the virus persist in the tissues of some individuals, causing prolonged symptoms."
There are problems with this though. Paxlovid has specifically had issues with viral clearance. with many patients, including Biden and Fauci becoming ill again with rebound infections. Biden toughed it out but Fauci took a second 5 day course of treatment. The company sought approval for longer courses of the drug and for second courses to be approved but was unsuccessful. Seems that the very fact of Rebound is what has enabled Paxlo to gain admittance to the trial. That is was given very early in the illness and when it failed to cleear Covid completely - it was successful at clearance much later in the infection cycle. So its initial failure somehow makes it a candidate for LC !!!

We know SNG has demonstrated accelerated viral clearance in covid and COPD - and we also know it can be given immediately after infection and then all the way into ICU. we salso know our LC results are very good. All of this - if the same criteria is applied for all candidates - dshould mean SNG is a strong candidate for Recover as well as STRIVE.

The later effects of LC - those poor patients who were damaged permanently by Delta - will be beyond SNG and certainly beyond Paxlovid's help but if stage 1 of LC is ongoing viral damage - as we know it is and this is being targeted by Recover then we SHOULD be a candidate

sorry Aether I think it's the usual fans 33 likes and 6 retweets though but no-one with an obvious pharma connection. Most of them look like you might find them in the pharmacy rather than working for Big pharma.

intriguing - front and centre doesn't necessarily imply the guv'nor anymore, but it would be odd in a group shot of emplyees to not shuffle either RM or the man making the presentation PM - into the middle. (or for that accidentally central lower ranks figure to not remove himself into the second row.
Smartphone snaps are of course casual affairs - but for fun it still suggests the possibility of someone senior from an outside group.

and the woman ?

Mark with a k. Bottle of Diamond White to the person who gets it.

Mani these sites are continually updated.

We discussed this in 2020 Mani - it's not relevant to the present situation, which has lots of promising things possibly happening already. You might as well post a link to Clinigen's MAP.

yeah - forget this. If we're lucky they might give us a trial - they're not going to put us on CTAP.
If something comes along and knocks out everything - as may well happen - the company should apply for EUA

Accidental most like - but entirely possible those pesky Central Committee boys dreamt it deliberately - as it has wrought tremendous destruction to the West (albeit with a certain amount of collateral damage )
China is the enemy of all free nations - make no doubt of that.

V interesting Joey. I don't understand half of it of course but it's hugely well written and resourced. Both sides have been asking the other side to prove their case since this started and it seems the Senate committee has decided it's up to the Zoonotics mob to do the proving and not the other way round.

Sorry Fruits the man in the middle - Dr Mark... you can read part of his name tag if you zoom in